Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 2 3

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Breast Neoplasms 5Stomatitis 3Head and Neck Neoplasms 3Fatigue 3Colorectal Neoplasms 3Pain 2Multiple Myeloma 2Lung Neoplasms 2Carcinoma, Hepatocellular 2Ulcer 1Trauma, Nervous System 1Spondylitis, Ankylosing 1Skin Neoplasms 1Schwannomatosis 1Rectal Neoplasms 1Psoriasis 1Pleural Effusion, Malignant 1Pancreatic Cyst 1Ovarian Neoplasms 1Non-functioning Pituitary Adenoma 1Neurofibromatosis 1 1Neurilemmoma 1Neoplasms 1Myelodysplastic Syndromes 1Metastatic Non-Squamous Non-Small Cell Lung Cancer 1Mesothelioma 1Malignant Neoplasm of Colorectum 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma 1

Interventions

Bevacizumab 234Fluorouracil 220Oxaliplatin 216Irinotecan 215Leucovorin 199Capecitabine 153Cetuximab 146Panitumumab 70Folfox protocol 51regorafenib 43Radiotherapy 38pembrolizumab 37IFL protocol 36HMPL-013 36trifluridine tipiracil drug combination 32Nivolumab 32Drug Therapy 26Neoadjuvant Therapy 24Trifluridine 18Celecoxib 18tislelizumab 17XELOX 17sintilimab 16Trastuzumab 16durvalumab 15atezolizumab 15aflibercept 15Chemotherapy, Adjuvant 15Biopsy 15apatinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Colorectal Neoplasms × Saline Solution × Clear all
NCT02134925 2026-05-28

Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps

National Cancer Institute (NCI)

Phase 2 Active not recruiting
110 enrolled 12 charts
Gastrointestinal

Colorectal Neoplasms

NCT00614393 2018-08-08

Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)

Merck Sharp & Dohme LLC

Phase 2 Completed
558 enrolled 17 charts
Gastrointestinal

Colorectal Neoplasms

NCT00851045 2015-10-12

Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer

Bristol-Myers Squibb

Phase 2 Completed
17 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡